<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01688544</url>
  </required_header>
  <id_info>
    <org_study_id>08-112</org_study_id>
    <nct_id>NCT01688544</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism</brief_title>
  <official_title>Phase 1 Study to Evaluate the Effect of CYP Polymorphism and Gender on the Pharmacokinetics and Pharmacodynamics of Ilaprazole After Multiple Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ilaprazole is a novel proton pump inhibitor and metabolized by CYP3A4 and 2C19. Thus genetic
      polymorphisms of CYP3A4 and 2C19 may have effect on the pharmacokinetics and pharmacodynamics
      of Ilaprazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effects of genetic polymorphisms on the pharmacokinetics or pharmacodynamics were measured in
      healthy Korean volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour intragastric ph</measure>
    <time_frame>After 7 days dosing of Ilaprazole 10 mg</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (Cmax, AUC) of Ilaprazole and its metabolite</measure>
    <time_frame>After 7 days dosing of Ilaprazole</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Gastrin level</measure>
    <time_frame>After 7 days dosing of Ilaprazole</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ilaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.
After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole</intervention_name>
    <description>Ilaprazole 10 mg for 7 days</description>
    <arm_group_label>Ilaprazole</arm_group_label>
    <other_name>2-[(4methoxy-3-methyl)-2-pyridinyl] methylsulfinyl-</other_name>
    <other_name>5-(1H-pyrrol-1yl)-1H-benzimidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adult volunteer between 20 and 45 years of age and within 20% of ideal body
             weight

          -  No congenital or acquired chronic disease

          -  appropriate for the study judging from examinations (hematology, chemistry, urinalysis
             and so on), vital sign and ECG results

          -  sign the informed consent form prior to study participation

        Exclusion Criteria:

          -  received any metabolizing enzymes or transporters inducing or inhibiting drugs like
             barbiturates within 1 month prior to the date of first drug administration

          -  history of hypersensitivity against drugs or clinically significant allergic diseases

          -  abnormal laboratory results

          -  positive result for helicobacter pylori infection from the Urea Breath Test

          -  alcohol or drug abuser

          -  pregnant or lactating

          -  donated whole blood within 60days prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JaeGook Shin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hoapital Clinical Trial Center</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2012</study_first_posted>
  <last_update_submitted>September 19, 2012</last_update_submitted>
  <last_update_submitted_qc>September 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Jae-Gook Shin</investigator_full_name>
    <investigator_title>Department of Pharmacology and Pharmacogenomics Research Center</investigator_title>
  </responsible_party>
  <keyword>Ilaprazole</keyword>
  <keyword>Intragastric pH</keyword>
  <keyword>Serum Gastrin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

